Australian biotech market today 08.04.09
08 April, 2009 by Kate McDonaldPharmaxis, Novogen, Progen, IDT, Clinuvel
Australian biotech market today 07.04008
07 April, 2009 by Kate McDonaldCellestis, Mesoblast, Tissue Therapies, Progen, Probiotec
Australian biotech market today 03.04.09
03 April, 2009 by Staff WritersStarpharma, Atcor, Bionomics, Circadian, CSL, Cochlear, Mesoblast, Pharmaxis
How to save the Australian biotechnology industry
02 April, 2009 by Kate McDonaldSaving biotech, growing muscle, finding flukes and Merv Jacobson speaks, all in the March/April 2009 issue of Australian Life Scientist, out now
Pharmaxis finishes Phase III dosing
02 April, 2009 by Kate McDonaldClinical milestone achieved in cystic fibrosis Phase III trial
Polartechnics in merger talks
02 April, 2009 by Kate McDonaldPolartechnics in talks to merge with secret suitor
Australian biotech market today 02.04.09
02 April, 2009 by Kate McDonaldPharmaxis, Mesoblast, CathRx, Fluorotechnics, Sonic, Avita, Biota
Speeding up clinical trials
02 April, 2009 by Staff WritersEvado releases clinical trials data collection service
Australian biotech market today 31.03.09
31 March, 2009 by Kate McDonaldPharmaxis, Cochlear, CSL, HeartWare, Sirtex, Progen
Cane toads the meat in the ant’s sandwich
31 March, 2009 by Kate McDonaldTeam Bufo may have found cane toad’s Achilles heel – meat ants
Australian biotech market today 30.03.09
30 March, 2009 by Staff WritersProgen, Cytopia, Avexa, Acrux, Biota, Cellestis
ChemGenex scores high on leukaemic stem cells
30 March, 2009 by Kate McDonaldChemGenex’ lead candidate kills cancer stem cells in animal model
Patent echoes for Viralytics
30 March, 2009 by Kate McDonaldViralytics granted patent in US for oncolytic echoviruses
TGR’s Crouch wins BioBusiness award
30 March, 2009 by Kate McDonaldTGR BioSciences CSO Michael Crouch wins Advancing BioBusiness Award
Biota partner to market
30 March, 2009 by Kate McDonaldBiota’s partner Daiichi Sankyo applies for marketing licence, finishes Phase III enrolment
